Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis

Sabina Halappanavar, Monita Sharma, Silvia Solorio-Rodriguez, Hakan Wallin, Ulla Vogel, Kristie Sullivan and Amy J. Clippinger

No 33, OECD Series on Adverse Outcome Pathways from OECD Publishing

Abstract: Lung fibrosis is a dysregulated or exaggerated tissue repair process resulting in the thickening or scarring of lung tissue. It involves the presence of sustained or repeated exposure to a stressor and intricate dynamics between several inflammatory and immune response cells, and the microenvironment of the alveolar-capillary region consisting of both immune and non-immune cells, and the lung interstitium. This AOP is applicable to a broad group of stressors of diverse properties e.g. metal dusts, pharmacological products, fibres, microorganisms, chemicals, including novel technology-enabled stressors such as nanomaterials. This AOP is referred to as AOP 173 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki).

Keywords: Inflammation; Lung fibrosis; Nanomaterials; Pulmonary fibrosis (search for similar items in EconPapers)
Date: 2023-12-12
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1787/10372cb8-en (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oec:envaad:33-en

Access Statistics for this paper

More papers in OECD Series on Adverse Outcome Pathways from OECD Publishing Contact information at EDIRC.
Bibliographic data for series maintained by ().